更正：病例报告：一名间变性甲状腺癌患者经多模式放疗、安罗替尼和托瑞帕利单抗联合治疗后实现显著且持续的缓解。
Correction: Case Report: Remarkable and sustained remission of an anaplastic thyroid carcinoma patient to the combined treatment of multimodal radiotherapy, anlotinib and toripalimab.
作者信息
Xing Yurou, Wu Xuehu, Li Zhihui, Wu Xin
机构信息
Thoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Oncology, Minda Hospital of Hubei Minzu University, Enshi, China.
出版信息
Front Oncol. 2025 Jul 3;15:1649567. doi: 10.3389/fonc.2025.1649567. eCollection 2025.
Abstract
[This corrects the article DOI: 10.3389/fonc.2025.1491918.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2025.1491918。]
相似文献
1
Correction: Case Report: Remarkable and sustained remission of an anaplastic thyroid carcinoma patient to the combined treatment of multimodal radiotherapy, anlotinib and toripalimab.更正：病例报告：一名间变性甲状腺癌患者经多模式放疗、安罗替尼和托瑞帕利单抗联合治疗后实现显著且持续的缓解。
Front Oncol. 2025 Jul 3;15:1649567. doi: 10.3389/fonc.2025.1649567. eCollection 2025.
2
Case Report: Remarkable and sustained remission of an anaplastic thyroid carcinoma patient to the combined treatment of multimodal radiotherapy, anlotinib and toripalimab.病例报告：一名间变性甲状腺癌患者经多模态放疗、安罗替尼和托瑞帕利单抗联合治疗后实现显著且持续的缓解。
Front Oncol. 2025 May 21;15:1491918. doi: 10.3389/fonc.2025.1491918. eCollection 2025.
3
Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis.免疫疗法或基于抗血管生成药物的治疗策略与化疗作为广泛期小细胞肺癌一线治疗的疗效和安全性：一项网状Meta分析。
Front Pharmacol. 2025 Jun 9;16:1539246. doi: 10.3389/fphar.2025.1539246. eCollection 2025.
4
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.托法替布联合贝伐珠单抗对比索拉非尼作为晚期肝细胞癌一线治疗的疗效（HEPATORCH）：一项随机、开放标签的3期试验
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20.
5
Efficacy of combined immunotherapy and targeted therapy in overcoming barriers to postoperative recurrence in squamous subtype anaplastic thyroid carcinoma with abscess: a case report and literature review.免疫治疗联合靶向治疗克服伴脓肿的鳞状细胞亚型间变性甲状腺癌术后复发障碍的疗效：一例报告及文献综述
Front Oncol. 2025 Mar 19;15:1477954. doi: 10.3389/fonc.2025.1477954. eCollection 2025.
6
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF-Mutated Anaplastic Thyroid Carcinoma.达拉非尼/曲美替尼联合检查点抑制用于BRAF突变型间变性甲状腺癌的治疗
Thyroid. 2024 Mar;34(3):336-346. doi: 10.1089/thy.2023.0573. Epub 2024 Feb 13.
7
Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: A systematic review and meta-analysis of randomized controlled trials.特瑞普利单抗联合治疗癌症的临床结局和免疫评估：一项随机对照试验的系统评价和荟萃分析。
Int Immunopharmacol. 2023 Dec;125(Pt B):111176. doi: 10.1016/j.intimp.2023.111176. Epub 2023 Nov 8.
8
Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.探索免疫疗法在滤泡细胞源性甲状腺癌治疗中的作用。
Immunotherapy. 2025 Jan;17(1):47-55. doi: 10.1080/1750743X.2025.2455922. Epub 2025 Feb 3.
9
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.新型免疫检查点抑制剂联合治疗与化疗作为广泛期小细胞肺癌一线治疗的疗效和安全性：一项网络荟萃分析。
Thorac Cancer. 2024 May;15(15):1246-1262. doi: 10.1111/1759-7714.15310. Epub 2024 Apr 16.
10
A case of selpercatinib treatment for anaplastic thyroid carcinoma resulting in abscess formation.1例使用塞尔帕替尼治疗间变性甲状腺癌导致脓肿形成的病例。
Int Cancer Conf J. 2024 Jun 27;13(4):387-390. doi: 10.1007/s13691-024-00694-2. eCollection 2024 Oct.
Zotero 插件